According to the study’s abstract, the Atenolol study of 1996 demonstrated that perioperative beta-blockade reduced post-surgical mortality. The current study tests whether a difference exists in mortality rates between patients receiving perioperative atenolol and metoprolol.
The study divided high-risk inpatients at San Francisco Veterans Affairs Medical Center since 1996 into two groups: patients who received perioperative atenolol only and patients who received metoprolol only. Propensity matching analysis was used to correct for differences in population risk factors.
The analysis showed that thirty-year mortality and one-year mortality was less likely for patients receiving atenolol than those receiving metoprolol.
Read the abstract on the study in Anesthesiology.
–Anesthesiologist on the Move: Dr. Michael Semenovski Joins BAETA as CMO
–Mass General Anesthesiologists to Provide Coverage at Martha’s Vineyard Hospital
–Botox-A Provides Only Limited Pain Relief for Cervical Myofascial Pain Syndrome
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
